Patent classifications
C12N9/80
DNA MODIFYING ENZYMES AND ACTIVE FRAGMENTS AND VARIANTS THEREOF AND METHODS OF USE
Compositions and methods comprising novel deaminase polypeptides for targeted editing of nucleic acids are provided. Compositions comprise deaminase polypeptides. Also provided are fusion proteins comprising a DNA-binding polypeptide and a deaminase of the invention. The fusion proteins include RNA-guided nucleases fused to deaminases, optionally in complex with guide RNAs. Compositions also include nucleic acid molecules encoding the deaminases or the fusion proteins. Vectors and host cells comprising the nucleic acid molecules encoding the deaminases or the fusion proteins are also provided.
Threonine Production Strain Having Attenuated Expression of the yafV Gene
Improved production of threonine from E. coli by fermentation is accomplished by attenuation but not elimination of the expression of either or both of the yafV gene encoding omega-amidase (a.k.a. 2-oxoglutaramate amidase). In certain embodiments the strain also has attenuated expression of the ilvA gene encoding threonine dehydratase (a.k.a threonine deaminase) in cases where there is attenuated express of the ilvA gene there is no need to express an exogenous cimA gene. In examples of both cases, attenuation is accomplished by engineering these genes to contain a weaker ribosome site. Further improvements in threonine production are made by expression of a heterologous pyruvate carboxylase gene exemplified by expression of the Corynebacterium glutamicum pyc gene under control of an E. coli promoter, to provide expression of pyruvate carboxylase that is not naturally expressed in E. coli. Still further improvement is accomplished by overexpression of the rhtC gene encoding the E. coli threonine transporter protein, exemplified by inserting a stronger ribosome binding site upstream of the open reading frame for the rhtC gene.
Threonine Production Strain Having Attenuated Expression of the yafV Gene
Improved production of threonine from E. coli by fermentation is accomplished by attenuation but not elimination of the expression of either or both of the yafV gene encoding omega-amidase (a.k.a. 2-oxoglutaramate amidase). In certain embodiments the strain also has attenuated expression of the ilvA gene encoding threonine dehydratase (a.k.a threonine deaminase) in cases where there is attenuated express of the ilvA gene there is no need to express an exogenous cimA gene. In examples of both cases, attenuation is accomplished by engineering these genes to contain a weaker ribosome site. Further improvements in threonine production are made by expression of a heterologous pyruvate carboxylase gene exemplified by expression of the Corynebacterium glutamicum pyc gene under control of an E. coli promoter, to provide expression of pyruvate carboxylase that is not naturally expressed in E. coli. Still further improvement is accomplished by overexpression of the rhtC gene encoding the E. coli threonine transporter protein, exemplified by inserting a stronger ribosome binding site upstream of the open reading frame for the rhtC gene.
<i>In vitro </i>and <i>in vivo </i>enrichment strategy targeting lymphocytes derived from vector transduced HSCs for therapy of disorders
The present invention is related to a dual promoter lentiviral vector and methods of use for the treatment of diseases and disorders, specifically lysosomal storage disorders.
<i>In vitro </i>and <i>in vivo </i>enrichment strategy targeting lymphocytes derived from vector transduced HSCs for therapy of disorders
The present invention is related to a dual promoter lentiviral vector and methods of use for the treatment of diseases and disorders, specifically lysosomal storage disorders.
Induction of protective immunity against antigens
Described herein are compositions and methods for making and using recombinant bacteria that are capable of regulated attenuation and/or regulated expression of one or more antigens from Clostridium Perfringens as vaccines to prevent necrotic enteritis (NE).
XANTHINE AMIDE HYDROLASE AND USE THEREOF
Provided are a xanthine amide hydrolase and the use thereof, particularly the use thereof for treating gout.
XANTHINE AMIDE HYDROLASE AND USE THEREOF
Provided are a xanthine amide hydrolase and the use thereof, particularly the use thereof for treating gout.
PROTEIN CROSSLINKING METHOD
The present invention addresses the problem of providing a novel protein crosslinking method. In the present invention, a crosslinking reaction is accelerated by causing both an oxidoreductase such as a laccase and a protein deamidase such as a protein glutaminase to act on a substrate protein.
PROTEIN CROSSLINKING METHOD
The present invention addresses the problem of providing a novel protein crosslinking method. In the present invention, a crosslinking reaction is accelerated by causing both an oxidoreductase such as a laccase and a protein deamidase such as a protein glutaminase to act on a substrate protein.